🧬 Tumor Marker Summary for Ovarian, Breast, Colorectal & Pancreatic Cancers
Marker | Full Name | Organ/System | Associated Cancer | Fasting Required? | Normal Range |
---|
1. CA 125 (Cancer Antigen 125)
- 🧠 Organ: Ovaries
- 🎯 Used For:
- Monitoring epithelial ovarian cancer
- Evaluating treatment response and detecting recurrence
- Sometimes used to evaluate pelvic masses
- 📈 High CA125:
- Ovarian cancer
- Endometriosis, menstruation, pregnancy
- Liver disease, peritonitis
- ✅ Fasting: Preferred but not mandatory
- ✅ Normal Range: < 35 U/mL
- ⚠️ Note: Not reliable for screening due to many false positives in benign conditions
2. CA 15-3 (Cancer Antigen 15-3)
- 🧠 Organ: Breast
- 🎯 Used For:
- Monitoring breast cancer (especially advanced/metastatic)
- Detecting recurrence post-treatment
- 📈 High CA 15-3:
- Breast cancer (especially stage III/IV)
- Lung, liver, ovarian cancers
- Benign liver disorders, endometriosis
- ✅ Fasting: Recommended
- ✅ Normal Range: < 30 U/mL
- ⚠️ Not useful for early-stage detection or screening
3. CEA (Carcinoembryonic Antigen)
- 🧠 Organ: Primarily colorectal, also lung, pancreatic, breast, and stomach
- 🎯 Used For:
- Monitoring colorectal cancer progression and recurrence
- Evaluating treatment success
- 📈 High CEA:
- Colorectal cancer
- Lung, pancreatic, gastric, breast cancers
- Smoking, liver cirrhosis, IBD (mild elevations)
- ✅ Fasting: Yes (especially for baseline)
- ✅ Normal Range:
- Non-smoker: < 3 ng/mL
- Smoker: < 5 ng/mL
4. CA 19-9 (Carbohydrate Antigen 19-9)
- 🧠 Organ: Pancreas
- 🎯 Used For:
- Monitoring pancreatic adenocarcinoma
- Assessing therapy response or recurrence
- 📈 High CA 19-9:
- Pancreatic, bile duct, gastric cancers
- Pancreatitis, obstructive jaundice (non-cancer causes)
- ✅ Fasting: Yes
- ✅ Normal Range: < 37 U/mL
- ⚠️ Not effective as a screening test due to low sensitivity in early-stage pancreatic cancer
📊 Comparison Summary Table
Marker | Primary Use | Cancer Types | Best Used For |
---|
CA 125 | Ovarian cancer monitoring | Ovarian, endometrial, peritoneal | Tracking treatment & recurrence |
CA 15-3 | Advanced breast cancer tracking | Breast, lung, ovarian | Disease burden & response |
CEA | Colorectal cancer monitoring | Colorectal, lung, pancreatic | Post-treatment surveillance |
CA 19-9 | Pancreatic cancer monitoring | Pancreatic, gastric, biliary | Prognosis, disease progression |
⚠️ Key Points
- Tumor markers are not diagnostic tools alone. They must be interpreted with:
- Imaging (CT, MRI, PET)
- Clinical history
- Biopsy (for definitive diagnosis)
- Mild elevations can occur in benign conditions like inflammation, liver disease, or pregnancy
🧪 Recommended Companion Tests
If Marker Is Elevated... | Consider Also Testing |
---|
CA 125 | Pelvic ultrasound, transvaginal scan, HE4 |
CA 15-3 | CEA, CA 27.29, Breast imaging (mammogram/USG) |
CEA | CT/MRI of abdomen/pelvis, Colonoscopy |
CA 19-9 | Liver function tests, abdominal imaging |